Systemic resistin is increased in type 2 diabetic patients treated with loop diuretics

Area of Science:

• Endocrinology
• Metabolic Syndrome
• Immunology

Background:

• Resistin's role in human obesity and insulin resistance is debated, with conflicting results.
• In humans, resistin is mainly from monocytes/macrophages, suggesting a link to macrophage activation.

Purpose of the Study:

• To investigate the association between serum resistin levels and type 2 diabetes (T2D), obesity, and renal dysfunction.
• To explore the relationship between systemic and monocyte-released resistin and clinical parameters.

Main Methods:

• Comparison of systemic and monocyte-released resistin levels in T2D patients, overweight, and normal-weight controls.
• Correlation analysis of serum resistin with body mass index, age, gamma-glutamyltransferase, fasting glucose, and interleukin-6.
• Assessment of resistin levels in patients treated with various medications, including loop diuretics.

Main Results:

• Systemic and monocyte-released resistin levels were similar across T2D, overweight, and normal-weight groups.
• Serum resistin modestly correlated with gamma-glutamyltransferase, fasting glucose, and interleukin-6 after adjusting for BMI and age.
• Loop diuretic use was associated with considerably higher systemic resistin, while furosemide reduced monocyte-released resistin.

Conclusions:

• Increased serum resistin in humans is associated with changes related to renal dysfunction, not obesity or type 2 diabetes.
• Medications like loop diuretics may influence serum resistin levels.
• Resistin's association with metabolic parameters is modest and potentially confounded by other factors.